Ice Bear Therapeutics SPC
Biotechnology company focused on developing a new insulin manufacturing approach that uses engineered mammalian cell lines and continuous bioreactor operations to increase output, reduce resource use, and lower cost of goods. Headquartered in Seattle, Washington, the company describes itself as a registered Social Purpose Company with global manufacturing partners in New Jersey and India and plans to develop biosimilar insulin candidates.
Industries
Nr. of Employees
small (1-50)
Ice Bear Therapeutics SPC
Products
Biosimilar Lispro (fast-acting insulin)
A biosimilar candidate of fast-acting lispro insulin intended for pre-meal administration to provide rapid glycemic support for patients with type 1 diabetes. Company forecasts commercial availability in 2030.
Biosimilar Glargine (long-acting insulin)
A biosimilar candidate of long-acting glargine insulin currently in evaluation by the company.
Biosimilar Lispro
Biosimilar Lispro is a fast-acting insulin taken before meals to provide immediate support for patients with type 1 diabetes. Forecasted for commercial release in 2030.
Biosimilar Glargine
Biosimilar Glargine is a long-acting insulin currently under evaluation by Ice Bear Therapeutics.
Biosimilar Lispro (fast-acting insulin)
A biosimilar candidate of fast-acting lispro insulin intended for pre-meal administration to provide rapid glycemic support for patients with type 1 diabetes. Company forecasts commercial availability in 2030.
Biosimilar Glargine (long-acting insulin)
A biosimilar candidate of long-acting glargine insulin currently in evaluation by the company.
Biosimilar Lispro
Biosimilar Lispro is a fast-acting insulin taken before meals to provide immediate support for patients with type 1 diabetes. Forecasted for commercial release in 2030.
Biosimilar Glargine
Biosimilar Glargine is a long-acting insulin currently under evaluation by Ice Bear Therapeutics.
Services
Coordination with global manufacturing partners to produce insulin using the company's mammalian cell line and continuous manufacturing approach.
Coordination with global manufacturing partners to produce insulin using the company's mammalian cell line and continuous manufacturing approach.
Expertise Areas
- Bioprocessing and continuous manufacturing
- Therapeutic protein and biosimilar development
- Mammalian cell line development
- Regulatory compliance for biologics
Key Technologies
- Mammalian cell line engineering
- Continuous bioreactors / continuous bioprocessing
- Protein expression and secretion systems
- Biosimilar development and formulation